Skye Bioscience is a biopharmaceutical company developing next-generation molecules to treat obesity and metabolic diseases. Self-described efforts focus on advancing first-in-class drugs to provide enhanced health outcomes.

Skye Bioscience

Skye Bioscience Inc. | 2,145 followers on LinkedIn. Unlocking new therapeutic pathways for metabolic health | Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.  Skye&#39;s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

Annalisa Jenkins

Vice President, Regulatory Affairs & Quality Assurance

Rhea Williams

President & CEO at Skye Bioscience, Inc.

Punit Dhillon

Chief Financial Officer

Kaitlyn Arsenault, CPA

Skye Bioscience Inc.

Skye hosted a satellite presentation on Nov. 5th during ObesityWeek 2024. Discover how Skye's drug, nimacimab, stands out by achieving effective peripheral CB1 inhibition without central exposure (and its risk of neuropsychiatric adverse events), leading to powerful benefits: dose-dependent weight loss, fat mass reduction with lean mass preservation, and improved glycemic control. Watch our full presentation here: https://lnkd.in/gxx2PbdP

Preliminary data from Skye's newly-developed diet-induced obesity (DIO) model in mice fulfilled its initial objective of showing that peripheral CB1 inhibition achieves significant weight loss without relying on central activity and its risk of neuropsychiatric adverse events. Skye’s peripherally-targeting antibody, nimacimab, a CB1 inverse agonist and antagonist, achieved dose-dependent weight loss of up to 16% compared to vehicle. Read the full article here: https://bit.ly/4fQ49B9

We are looking forward to participating in upcoming healthcare conferences. Available webcasts will be accessible on our website. Click here to read the full article: https://bit.ly/3YAsgwH

“It is clear that with increased restriction from the brain, nimacimab provides a potential safety advantage over a small molecule approach..." Skye CEO, Punit Dhillon said. Read the full article here: https://bit.ly/47EeaOX

We are looking forward to our formal presentation and investor meetings at #CantorHCC where Punit and Puneet will be representing Skye. View the webcast live on Sept 19 at 8:35am ET or the archive: https://lnkd.in/gRxa-jea

Skye looks forward to its fireside chat and meetings at Morgan Stanley on Friday, September 6th at 1:50 pm ET. Join the Webcast here, or watch the archived version: https://lnkd.in/gkFax6_C #MSHealthcare

Skye welcomes Puneet S. Arora, MD, MS, FACE, in the newly created role of Chief Medical Officer (CMO). Dr. Arora was previously at Lassen Therapeutics, Principia Biopharma, a Sanofi company, and Genentech. He is an endocrinologist with extensive experience in metabolic diseases, including obesity. Read the full article here: https://bit.ly/47es2PA

Skye will participate in the following upcoming healthcare investment conferences: - Morgan Stanley - Cantor Global Healthcare Conference - Bank of America World Medical Innovation Forum Available webcasts will be accessible on Skye’s website: https://bit.ly/3MiaecK

CBeyond(TM) will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab. Read the full article here: https://bit.ly/3T0hw8H

We're pleased to have broad sellside interest in nimacimab, our differentiated CB1 inhibitor focused on weight loss, and have a strong investment conference calendar through year-end.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

SKYE

COM:SKYEBIOSCIENCE

Skye Bioscience

Last Close

4.28

21/11 20:19

Market Cap

129.85M

Beta: -

Volume Today

71.64K

Avg: -

Filings Not Available